Evaluation of Tissue Perfusion in Peripheral Arterial Disease (EVTI-PAD) (EVTI-PAD)
Evaluation of Tissue Perfusion in Patients With Lower Extremity Peripheral Arterial Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Florian K Enzmann, MD, PhD
- Phone Number: 82196 004343512504
- Email: florian.enzmann@i-med.ac.at
Study Contact Backup
- Name: Michaela Kluckner, MD
- Phone Number: 83496 004343512504
- Email: michaela.kluckner@i-med.ac.at
Study Locations
-
-
Tyrol
-
Innsbruck, Tyrol, Austria, 6020
- Recruiting
- Department of Vascular Surgery, Medical University Innsbruck
-
Contact:
- Florian Enzmann, MD, PhD
- Email: florian.enzmann@i-med.ac.at
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients with symptomatic peripheral arterial disease (Rutherford categories 3-6) requiring revascularization.
Exclusion Criteria:
- patients younger than 18 years
- patients unable to give consent without legal guardians
- iodine allergy
- hyperthyroidism
- allergy to indocyanine green
- Glomerular filtration rate <30ml/min/1.73m2
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Transcutaneous oxygen pressure
Time Frame: Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure
|
Change in transcutaneous oxygen pressure is measured before and after the revascularization procedure.
|
Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
WIfI stage
Time Frame: Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure
|
Change in WIfI (wound, ischemia, foot infection) stage is documented before and after the revascularization procedure.
|
Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure
|
|
Rutherford category
Time Frame: Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure
|
Change in Rutherford category is documented before and after the revascularization procedure.
|
Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure
|
|
Primary patency
Time Frame: Post-procedural (within 5 days) and 3 months after the index procedure
|
Primary patency of the treated arterial lesion is documented after the procedure
|
Post-procedural (within 5 days) and 3 months after the index procedure
|
|
Secondary patency
Time Frame: Post-procedural (within 5 days) and 3 months after the index procedure
|
Secondary patency of the treated arterial lesion is documented after the procedure
|
Post-procedural (within 5 days) and 3 months after the index procedure
|
|
Limb salvage
Time Frame: Post-procedural (within 5 days) and 3 months after the index procedure
|
Limb salvage of the treated extremity is documented after the procedure
|
Post-procedural (within 5 days) and 3 months after the index procedure
|
|
Ankle-brachial index (ABI)
Time Frame: Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure
|
Change in ABI is documented before and after the revascularization procedure.
|
Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure
|
|
Fluorescence angiography
Time Frame: Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure
|
Change in fluorescence angiography is documented before and after the revascularization procedure.
|
Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure
|
|
Survival
Time Frame: Post-procedural (within 5 days) and 3 months after the index procedure
|
Survival of patients after the revascularization.
|
Post-procedural (within 5 days) and 3 months after the index procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997 Sep;26(3):517-38. doi: 10.1016/s0741-5214(97)70045-4. Erratum In: J Vasc Surg 2001 Apr;33(4):805.
- Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, Mills JL, Ricco JB, Suresh KR, Murad MH, Aboyans V, Aksoy M, Alexandrescu VA, Armstrong D, Azuma N, Belch J, Bergoeing M, Bjorck M, Chakfe N, Cheng S, Dawson J, Debus ES, Dueck A, Duval S, Eckstein HH, Ferraresi R, Gambhir R, Gargiulo M, Geraghty P, Goode S, Gray B, Guo W, Gupta PC, Hinchliffe R, Jetty P, Komori K, Lavery L, Liang W, Lookstein R, Menard M, Misra S, Miyata T, Moneta G, Munoa Prado JA, Munoz A, Paolini JE, Patel M, Pomposelli F, Powell R, Robless P, Rogers L, Schanzer A, Schneider P, Taylor S, De Ceniga MV, Veller M, Vermassen F, Wang J, Wang S; GVG Writing Group for the Joint Guidelines of the Society for Vascular Surgery (SVS), European Society for Vascular Surgery (ESVS), and World Federation of Vascular Societies (WFVS). Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg. 2019 Jul;58(1S):S1-S109.e33. doi: 10.1016/j.ejvs.2019.05.006. Epub 2019 Jun 8. Erratum In: Eur J Vasc Endovasc Surg. 2020 Mar;59(3):492-493. Eur J Vasc Endovasc Surg. 2020 Jul;60(1):158-159.
- Halliday A, Bax JJ. The 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in Collaboration With the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018 Mar;55(3):301-302. doi: 10.1016/j.ejvs.2018.03.004. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1440/2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.